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Abstract: The pathogenesis of Crohn’s disease (CD) is multifactorial and the activation of 
speciﬁ  c pathways of immunological system is important. In particular, the adhesion molecules 
(integrins) mediate the selective binding between the leukocytes and the endothelial cells 
regulating the migration of leukocytes into the normal and inﬂ  amed intestine. Selective adhesion 
molecule inhibitors interfere with the migration of leukocytes to the sites of inﬂ  ammation by 
targeting adhesion molecules (α4-integrin or α4β7-integrin). Natalizumab is a humanized IgG4 
anti-α4-integrin monoclonal antibody that inhibits both α4β7-integrin/mucosal addressin-cell 
adhesion molecule-1 (MadCAM-1) interaction and α4β1/vascular-cell adhesion molecule-1 
(VCAM-1) binding. Pooled data from the four studies, analyzed in a Cochrane review, suggest 
that natalizumab is effective for induction of clinical response and remission in patients with 
moderately to severely active CD. In particular, natalizumab may be beneﬁ  cial for patients 
with active inﬂ  ammation or chronically active disease despite the use of conventional therapies 
with high level of C-reactive protein values at baseline time. Nevertheless, many problems about 
the utilization of natalizumab in CD remain unsolved (such as the high placebo response, the 
ﬁ  nal deﬁ  nition of dosage and timing schedule, the deﬁ  nition of outcomes and the development 
of adverse events).
Keywords: Crohn’s disease, biological therapy, natalizumab, progressive multifocal 
leukoencephalopathy
Introduction
The etiology of inﬂ  ammatory bowel diseases (IBD) has not yet been fully addressed, 
but there has been remarkable progress in the understanding of this ﬁ  eld in the past 
decade. In normal bowel, the immune reaction is sophistically regulated while keeping 
a balance between the effectors and the regulators, and as a result the homoeostasis of 
the gut is maintained. A lot of evidence indicates that mucosal immunity is dysregulated 
in the bowel of IBD patients.
In particular, the pathogenesis of Crohn’s disease (CD) is multifactorial, including 
genetic factors, environmental factors, and immunological factors. For the development 
of intestinal inﬂ  ammation, the activation of the speciﬁ  c pathways of immunological 
system are important and the leukocyte trafﬁ  cking to the gut is an important step 
(Fiocchi 1998). Adhesion molecules, such as integrins, mediate the selective binding 
between the leukocytes and the endothelial cells and thus the migration of leuokocytes 
into normal and inﬂ  amed intestine. The main classical medical treatments for IBD 
are steroids and immunosuppressive agents which non-speciﬁ  cally reduce immunity 
and inﬂ  ammation. Recent advances in the understanding of the mechanisms of bowel 
inﬂ  ammation have led to a recent trend in development of biological therapies which 
selectively inhibit the action of molecules essential to the inﬂ  ammatory process 
(Nakamura et al 2006) (Figure 1). Major targets for such therapies are inﬂ  ammatory 
cytokines and their receptors, and adhesion molecules. Selective adhesion molecule 
inhibitors interfere with the migration of leucocytes to the sites of inﬂ  ammation by 
targeting adhesion molecules, such as α4-integrin or α4β7-integrin. In particular, Biologics: Targets & Therapy 2008:2(2) 276
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natalizumab, a humanized IgG4 anti α4-integrin monoclo-
nal antibody containing approximately 5% mouse-derived 
protein, inhibits both α4β7-integrin/MAdCAM-1 interaction 
and α4β1/VCAM-1 binding (Figure 2). The US Food and 
Drug Administration has approved natalizumab for multiple 
sclerosis with the requirement of mandatory participation in 
a risk-management and registry program.
Therapeutic targets of natalizumab
The integrins are a family of cell-surface glycoproteins 
involved in the adhesion, migration, and activation of immune 
cells. In particular, the integrins are adhesion molecules 
that confer mechanical stability on interactions between 
cells and their environment (Hynes 2002). They also act 
as cellular sensors and signaling molecules. All integrins are 
composed of non-covalently linked α and β chains. The α4-
integrin is expressed at a moderate or high level on almost 
all lymphocytes and to a lesser extent on monocytes and 
eosinophils. The α4-integrin chain dimerizes with either the 
β1 chain or the β7 chain. The α4β1-integrin is also known 
as very late antigen 4 or cCD49d-CD29, and the α4β7-
integrin is sometimes referred to as lamina propria-associated 
molecule-1. Natalizumab binds the α4 chain irrespective of 
its associated β chain and probably has therapeutic effects 
because it blocks the ability of α4β1 and α4β7 to bind to 
their respective endothelial counter-receptors, vascular-cell 
adhesion molecule-1 (VCAM-1), and mucosal addressin-
cell adhesion molecule-1 (MAdCAM-1). These molecular 
interactions are required for lymphocytes to enter the central 
nervous system (mediated by α4β1 and VCAM-1) and the 
intestine (mediated by α4β7 and MAdCAM-1). In fact, human 
and animal studies have suggested that the interaction between 
α4β7 and MAdCAM-1 is particularly important in mediating 
leukocyte homing to gut mucosa. Furthermore, studies of 
patients with IBD show that endothelial cells extracted 
from inﬂ  amed intestinal mucosa demonstrate increased α4-
dependent adhesiveness to leukocytes from patients with IBD 
in vitro (Binion et al 1998).
It is now well established that the recruitment of leuko-
cytes from the blood into virtually every tissue is regulated 
by sequential engagement of adhesion and signaling mol-
ecules on leukocytes and endothelial cells (Springer 1994; 
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Figure 1 Adhesion molecules (integrins) mediate the selective binding between the leukocytes and the endothelial cells to migrate from the vessels to the inﬂ  amed intestinal 
muocsa, through four phases: attachment, rolling, arrest, and transmigration. The toxic metabolites, cytokines, and chemioactractans, produced by the inﬂ  ammation source, induce 
and drive the trafﬁ  cking of immune cells to ﬁ  nal destination.Biologics: Targets & Therapy 2008:2(2) 277
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Butcher and Picker 1996; Von Andrian and Mackay 2000), 
described above. Leukocytes make an initial adhesive contact 
that allows them to slow down and roll along the vascular 
wall. This step, which is readily reversible, can be mediated 
by selectins, α4 integrins, or both. In order for the rolling 
leukocyte to stop, it must receive an activating signal, such 
as a signal from a chemokine, which switches integrins to a 
high afﬁ  nity state and allows the cell to arrest itself (Springer 
1994; Butcher and Picker 1996; Von Andrian and Mackay 
2000). Leukocytes are recruited into a tissue only if they are 
successful at undergoing each step. The two α4 integrins 
and their endothelial counter-receptors have a unique role in 
this multi step cascade because they are the only molecules 
known to mediate both rolling (when the integrins are in a 
low-afﬁ  nity state) and arrest (when they are in a high-afﬁ  nity 
state) (Alon et al 1995; Berlin et al 1995) (Figure 1).
Two main indications are currently investigated for 
natalizumab, multiple sclerosis and CD.
Multiple sclerosis (human equivalent 
of animal autoimmune encephalomyelitis)
The earliest evidence of α4-integrin mediated central 
nervous system disease came from studies of autoimmune 
encephalomyelitis, a T-cell mediated autoimmune disease 
that resembles multiple sclerosis, in animals (Yednock et al 
1992). Antibodies to α4 integrins reduce cellular inﬁ  ltration, 
inhibit the development of autoimmune encephalomyelitis, 
and halt the progression of disease or even reverse existing 
symptoms by preventing inﬂ  ammatory cells from crossing the 
blood – brain barrier. These ﬁ  ndings suggest that α4-integrin 
inhibitors should block the egress of pathogenic T-cells into 
unaffected regions of the central nervous system, where their 
stimulation by antigen would precipitate the inﬂ  ammation 
cascade. Such blockade may explain the effectiveness of 
natalizumab in preventing the formation of new lesions in 
patients with multiple sclerosis (Miller et al 2003), which is 
the human equivalent of auto-immune encephalomyelitis.
Crohn’s disease (CD)
The effects of natalizumab in patients with CD are likely to 
involve inhibition of the binding of α4β7 to MAdCAM-1. 
MAdCAM-1 is selectively expressed in venules in the gut 
and gut-associated lymphoid tissue (Butcher and Picker 
1996) (Figure 2). Animal models of colitis have shown that 
antibodies to α4β7 or MAdCAM-1 attenuate T-cell-mediated 
intestinal inﬂ  ammation (Hesterberg et al 1996; Picarella et al 
1997). However, VCAM-1 is also induced in inﬂ  ammatory 
bowel disease and predominates in some animal models of 
experimental colitis (Soriano et al 2000). The extent to which 
natalizumab exerts its therapeutic effects by inhibiting α4β1 
in addition to its blockade of α4β7 remains to be determined. 
Whatever the precise mechanism of natalizumab’s efﬁ  cacy in 
patients with CD, the drug had only partial anti-inﬂ  ammatory 
effects during the treatment periods (Ghosh et al 2003), sug-
gesting that intestinal inﬂ  ammation involves other pathways 
of leukocytes recruitment. Indeed, the inﬂ  ammatory inﬁ  ltrate 
in CD is dominated by neutrophils, which do not normally 
express α4 integrins, but instead rely on β2 integrins to 
travel to sites of inﬂ  ammation (Springer 1994). Neutrophils 
can express α4β1 once they have emigrated out of blood 
vessels (Kubes et al 1995), but it is questionable whether 
the inhibition of α4 integrins at this stage can interfere with 
leukocytes-mediated disease. The T-cells are essential for 
inducing the secondary signaling molecules in the gut, such 
as cytokines and chemokines that are needed to sustain 
neutrophil recruitment (Hesterberg et al 1996).
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Figure 2 Pharmacological targets of natalizumab. Several adhesion molecules are espressed on the surface of endothelial and immune system cells. In particluar, natalizumab inhibits 
the interaction between α4β1and α4β7 integrins expressed on the surface of T lymphocyte cells, and VCAM-1 and MAdCAM-1 expressed on the surface of endothelial cells.Biologics: Targets & Therapy 2008:2(2) 278
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Clinical studies in Crohn’s disease
Preclinical studies have shown that monoclonal antibodies 
against α4-integrin reduce inﬂ  ammation and symptoms of 
disease in tamarins with IBD (Podolsky et al 1993; Hesterberg 
et al 1996). After that, 2 pilot studies showed an improvement 
in signs and symptoms of patients with CD or ulcerative colitis 
(UC) treated with natalizumab (Gordon et al 2001, 2002). Four 
randomized, double-bind, placebo-controlled trials were then 
published and will be analyzed in detail in this review.
Study of Gordon et al (2001)
In this study, 35 adults with a conﬁ  rmed diagnosis of CD were 
screened and 30 patients randomized to receive the treatment 
from 2 centers in the UK. All patients included presented a 
clinical evidence of mild to moderately active CD (deﬁ  ned by 
a Crohn’s Disease Activity Index [CDAI] of 151 and 450). 
Oral corticosteroids were allowed if the dose was stable within 
2 weeks of study entry. Patients receiving 5-ASA drugs or 
azatioprine or 6-mercaptopurine were included if treatment 
had not been started within 2 months or the dose increased 
within 4 months of study entry. Exclusion criteria included: 
pregnancy or breast-feeding; patients weighing more than 
100 kg; patients with CDAI score 450; patients treated with 
cyclosporine, methotrexate, or tracolimus therapy; patients 
who had abdominal surgery within 3 months of entry or 
were considered likely to require surgery within 3 months of 
study entry; patients with an ileostomy or colostomy; patients 
with laboratory-confirmed intestinal infection; patients 
with a current or past malignant neoplasm. Two groups of 
patients were randomized to receive: an intravenous infusion 
of natalizumab (3 mg/kg; n = 18) or placebo (n = 12). The 
demographic characteristics of the patients at study entry 
were: 9/30 (30%) with perianal disease; 9/30 (30%) with 
ileal and colonic location; 8/30 (27.7%) with colonic alone 
location; and 12/30 (40%) with ileal alone location. The 
primary outcome was the change in mean CDAI at 2 weeks 
post infusion and clinical remission (deﬁ  ned as a CDAI 
score of less than 150). Other secondary outcomes included 
Inﬂ  ammatory Bowel Disease Questionnaire (IBDQ), serum 
levels of C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR), full blood count, peripheral blood T-cells and 
B cells, serum natalizumab and anti-natalizumab antibody 
concentration. Patients were evaluated at study entry and at 
weeks 1, 2, 4, 8, and 12 post infusion. Three patients withdrew 
form the study before completing 12 weeks (2 for intervention 
ineffective and 1 for loss to follow-up). Natalizumab-treated 
patients achieved signiﬁ  cant reductions in CDAI at 2 (p = 0.02) 
and 4 (p = 0.01) weeks after treatment compared with baseline, 
although results of between-groups comparisons with 
placebo-treated patients were not statistically signiﬁ  cant. By 
2 weeks 39% had experienced remission compared with 8% 
of the placebo group (p = NS). Remission was sustained to 
at least week 12 in two of the natalizumab-treated patients. 
The two observed differences between groups were not 
statistically signiﬁ  cant. A signiﬁ  cant improvement in mean 
IBDQ score occurred from 121 points at baseline to 140 
points at 4 weeks in patients who received natalizumab 
(p = 0.004). Patients who received natalizumab experienced a 
signiﬁ  cant reduction in CRP at 2 and 4 weeks compared with 
baseline levels (p = 0.02 at both time points) and a signiﬁ  cant 
reduction in ESR at 4 weeks only (p = 0.04). These changes 
did not differ signiﬁ  cantly from those in the placebo group. 
Two patients (11%) developed transient low-level non-anti-
idiotypic antibodies to natalizumab, detectable only at a single 
visit during the 12-week trial follow-up period. The most 
common adverse events reported in at least 20% of patients 
during the 12-week follow-up period were headache (50% of 
each treatment group), CD exacerbation (39% in natalizumab 
group and 42% in placebo group), and abdominal pain (22% in 
natalizumab group and 17% in placebo group). The frequency 
of these events did not differ signiﬁ  cantly between groups. 
Two natalizumab patients and 1 placebo patient required 
surgical resection of CD at 66, 69, and 70 days, respectively. 
A signiﬁ  cant increase in mean circulating lymphocyte counts 
occurred at 1, 2, and 4 weeks post infusion in natalizumab 
patients only. In this study the effects of natalizumab at a dose 
of 3 mg/kg appear to be relatively short-lived in patients with 
active CD. This ﬁ  nding may be related to the ﬁ  nding that the 
half-life of natalizumab is 4.8 days in IBD patients, shorter 
than the 8.7 days observed in healthy volunteers (Elan Pharma 
1997). In vitro leukocyte-saturation studies now suggest that 
a minimum serum concentration of approximately 3 μg/mL 
of natalizumab is required to produce appropriate saturation 
of at least 80% of membrane-bound α4 integrins (Elan 
Pharma Ltd, unpublished data, June 1999). The mean serum 
concentrations of natalizumab at 2 and 4 weeks post infusion 
were 4.91 and 0.99 μ/mL, respectively, suggesting perhaps 
that blockade of α4 integrins was suboptimal after a single 3 
mg/kg dose and that larger and/or more frequent doses might 
result in improved efﬁ  cacy.
Study of Ghosh et al (2003)
In this study, 248 adults (18 years of age) were recruited 
from 35 centers (Belgium, Czech Republic, Denmark, 
Germany, Israel, the Netherlands, Sweden, and the UK) for 
a 12-week induction trial. All patients included in the study Biologics: Targets & Therapy 2008:2(2) 279
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had clinical evidence of moderate to severe CD, deﬁ  ned by 
a CDAI of at least 220 but no more than 450. The exclu-
sion criteria were: patients who received methotrexate, 
cyclosporine, or any investigational drugs within 3 months 
prior to randomization; patients taking stable doses of aza-
thioprine or 6-mercaptopurine for less than 4 months prior 
to randomization; prior treatment with any antibody agent; 
current use of more than 25 mg/day of oral prednisolone 
or another corticosteroid at an equivalent dose; elemental 
diet or parenteral nutrition; infectious or neoplastic disease 
of the bowel; bowel surgery within 3 months prior to ran-
domization; the presence of an ileostomy; the presence of 
symptoms due mainly to ﬁ  brotic strictures; and a clinical 
impression that the patient would likely require abdominal 
surgery. The four treatment groups received 2 intravenous 
infusions 4 weeks apart at week zero and week 4, with fol-
lowing schedule: 2 infusions of placebo (n = 63); 1 infusion 
of natalizumab (3 mg/kg), and 1 infusion of placebo (n = 68); 
2 infusions of natalizumab (3 mg/kg; n = 66) and 2 infusions 
of natalizumab (6 mg/kg; n = 51). The primary outcome vari-
able was the proportion of patients who entered remission 
at week 6 (deﬁ  ning as a CDAI score of less than 150). The 
secondary outcome variable was the proportion of patients 
presenting clinical response (deﬁ  ning as a decrease in the 
CDAI score of at least 70 points from baseline). Other sec-
ondary outcome variables included the serum concentration 
of CRP, absolute neutrophil counts, serum antibodies against 
natalizumab, and health-related quality of life as measured 
by the IBDQ. The demographic characteristics of the patients 
at baseline were: 15.3% (38/248) ﬁ  stulizing disease; 54.8% 
(136/248) ileum and colon location; 23.8% (59/248) colon 
disease; 21.4% (53/248) only ileum disease. Patients were 
evaluated at baseline and weeks 2, 4, 6, 8, and 12. Of the 
244 patients who received at least 1 dose of the assigned 
study drug, 27 withdrew from the study before completing 
12 weeks (ineligibility [2/27], adverse events [8/27], lack 
efﬁ  cacy [7/27], patient’s request [3/27], loss to follow-up 
[2/27], and investigator’s decision [5/27]). The total numbers 
of patients who had adverse events during or after treatment 
were similar in the four groups (81% vs 77% vs 88% vs 78%) 
with very high value, even if without any serious adverse 
events. Antibodies binding to natalizumab were detected in 
13 natalizumab-treated patients (7%) at week 12.
The rate of remission in the group given 2 infusions of 6 mg/kg 
of natalizumab was not signiﬁ  cantly different from the rate 
in the placebo group at week 6 (primary outcome) such as 
in the group given 1 infusion of natalizumab (3 mg/kg). At 
weeks 4 and 8 the remission rate among the patients who 
received two 6 mg doses was signiﬁ  cantly superior to the 
rate in the placebo group (29% vs 14%, p = 0.028 and 43% vs 
16%, p   0.001, respectively). The group given 2 infusions 
of 3 mg/kg of natalizumab had a signiﬁ  cantly higher rate of 
clinical remission at weeks 4, 6, 8, and 12 than did the pla-
cebo group (29% vs 14% with p = 0.027, 44% vs 27% with 
p = 0.03, 41% vs 16% with p  0.001, and 42% vs 27% with 
p = 0.042). All three natalizumab groups had a signiﬁ  cantly 
higher rate of clinical response than did the placebo group 
at weeks 4, 6, 8 (with the higher value in the group received 
2 infusions of 3 mg/kg with maximum response rate level 
of 71% at week 6, with p  0.001), and at week 12 for the 
two groups that received 2 infusions of natalizumab (61% vs 
43%, p = 0.033 and 65% vs 43%, p = 0.018). Two infusions 
of natalizumab administered 4 weeks apart resulted in more 
durable clinical response than a single infusion and 2 infusions 
of 6 mg/kg had no advantage over 2 infusions of 3 mg/kg. 
All three natalizumab groups (1 infusion and 2 infusions at 
3 mg/kg or 6 mg/kg) had signiﬁ  cant improvement in mean 
IBDQ scores at week 6, as compared to placebo (155 vs 145, 
p = 0.008 for 1 infusion of 3 mg/kg, 163 vs 145, p  0.001 
for 2 infusions of 3 mg/kg, and 155 vs 145, p  0.001 for 
2 infusions of 6 mg/kg). By week 12, only the groups that 
received 2 infusions of natalizumab continued to have scores 
that were signiﬁ  cantly higher than in placebo group (161 vs 
145, p = 0.033 and 155 vs 145, p = 0.018 for 2 infusions of 
3 mg/kg and 2 infusions of 6 mg/kg, respectively). Patients 
treated with 2 infusions of natalizumab had a signiﬁ  cant 
decline from baseline in the serum levels of CRP only at week 
6, as compared with the placebo group (p  0.05). Finally 
there was a sustained increase in the mean lymphocyte count, 
ranging from 1.3 to 1.9 times the baseline value in each 
natalizumab group, remaining within normal range. The 
increase in circulating lymphocytes in natalizumab-treated 
patients may be a manifestation of the interruption of α4 
integrin-mediated migration of lymphocytes to extravascular 
lymphocytes. We can speculate that it should be a clinically 
signiﬁ  cant mechanism of action of natalizumab.
Study of Sandborn et al (2005)
In the ENACT-1 study, 905 adult patients with moderate to 
severe CD (deﬁ  ned by a baseline CDAI score of 220 to 450 
points) were recruited from 142 centers in North America, 
Europe, and selected countries around the world for a 12-
week induction trial. Concomitant medication, including 
stable doses of 5-ASA drugs, prednisone (25 mg/day), 
budesonide, azathioprine, 6-mercaptopurine, methotrexate, 
and antibiotics were permitted. Exclusion criteria included: Biologics: Targets & Therapy 2008:2(2) 280
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patients with short bowel syndrome, an ileostomy, a total 
colectomy, a stricture with obstructive symptoms, draining 
ﬁ  stulas, abdominal abscess, previous natalizumab treatment, 
or previous anti-tumor necrosis factor α (TNFα) therapy 
within 3 months prior to study entry. Enrolment of patients 
who were non-responders to anti-TNFα treatment was lim-
ited to a maximum of 30% of total study enrolment. Patients 
were randomized to receive an infusion of either 300 mg of 
natalizumab (n = 724) or placebo (n = 181) for a total of 3 
infusions given at weeks 0, 4, and 8. Patients were assessed 
at weeks 2, 4, 6, 8, 10, and 12. The IBDQ was administered 
to assess quality of life at weeks 0, 6, and 10. The primary 
outcome variable was response (deﬁ  ned as a reduction of 70 
points in the CDAI score from baseline) and remission at week 
10 (deﬁ  ned as a CAI score of less than 150). Other secondary 
outcome variables included serum levels of CRP and mean 
lymphocyte counts. Remission occurred at week 10 in 37% of 
natalizumab-treated patients and 30% of patients receiving pla-
cebo (p = 0.12). A clinical response at week 10 was observed in 
56% of patients treated with natalizumab and 49% of patients 
receiving placebo (p = 0.05). However, a subgroup analysis 
of 660 patients including those with active inﬂ  ammation at 
baseline (CRP concentration above the upper limit of normal) 
showed clinically and statistically signiﬁ  cant differences in 
response and remission rates. Among patients with elevated 
CRP concentrations at baseline 58% of natalizumab treated 
patients and 45% of patients in the placebo group experienced 
a clinical response at week 10 (p  0.05), while 40% and 28% 
respectively, entered clinical remission (p  0.05).
Patients who reached the primary end point of response at 
week 10 in the ENACT-1 study were randomly reassigned in 
the ENACT-2 study to receive either natalizumab or placebo 
every 4 weeks through week 56. Although the ENACT-1 
trial did not meet the primary end point of response at week 
10 with statistical signiﬁ  cance in the overall population, the 
rates of sustained response during the ENACT-2 study were 
signiﬁ  cantly higher among those who continued to receive 
natalizumab rather than being given placebo (61% vs 28%; 
p  0.001). The median time to the loss of response was also 
much longer among those receiving the antibody. The higher 
frequency of smokers among those receiving placebo in the 
ENACT-2 study, as compared with those receiving natalizumab 
(26% vs 16%), may have confounded the results, since smoking 
has been associated with increased CD activity.
Study of Targan et al (2007)
The ENCORE (Efﬁ  cacy of Natalizumab in Crohn’s disease 
Response and Remission) study was designed to conﬁ  rm 
the hypothesis generated from the subgroup analysis of the 
ENACT-1 trial that natalizumab is effective as an induction 
therapy in patients with moderately to severely active CD 
and active inﬂ  ammation characterized by elevated CRP 
concentrations. In the ENCORE study, 509 adult patients 
(from 832 patients screened) with moderately to severely 
active CD and objective evidence of active inﬂ  ammation 
(elevated CRP) were recruited from 114 centers in North 
America, Europe, and selected countries around the world 
for a 12-week induction trial. Patients with a CDAI score 
between 220 and 450 and CRP levels greater than the upper 
limit of normal were randomized to receive an infusion of 
either 300 mg natalizumab (n = 259) or placebo (n = 250) for 
a total of 3 infusions given at weeks 0, 4, and 8. Efﬁ  cacy and 
safety were assessed at weeks 4, 8, and 12. The demography 
characteristics of all patients at baseline were: 50% (254/509) 
with ileocolonic location; 26.4% (134/509) with colonic 
alone location; 24.7% (121/509) with ileal alone location. 
The primary outcome variable was clinical response by week 
8 (deﬁ  ned as a reduction of 70 points in the CDAI score 
from baseline that was sustained through week 12). Second-
ary outcome variables included the proportion of patients 
achieving a clinical remission by week 8 and through week 
12 and the proportion of patients in response or remission 
at any assessment, without considering mucosal healing as 
an important outcome.
The primary outcome (clinical response at week 8 sus-
tained through week 12) occurred in 48% (124 of 259) of 
natalizumab-treated patients compared with 32% (81 of 250) 
of patients receiving placebo (p  0.001). The secondary 
end point, remission at week 8 sustained through week 12, 
occurred in 26% (68 of 259) of patients randomized to receive 
natalizumab and 16% (40/250) of patients who received 
placebo (p = 0.002). At week 12 (secondary end point) 
60% (155/259) of patients receiving natalizumab vs 44% 
(109/250) of those administered placebo (p  0.001) were 
in response and 38% (97/259) vs 25% (63/250) respectively 
(p = 0.001) were in remission. Treatment effect was evident 
as early as the ﬁ  rst assessment. The median time to clinical 
response for patients in the natalizumab treatment group was 
31 days compared with 51 days in the placebo group. The 
median time to clinical remission was 86 days for patients 
receiving natalizumab. At week 12 a greater improvement in 
mean total IBDQ score was observed among patients in the 
natalizumab group compared with those in the placebo group 
(p  0.001). During the study, mean CRP concentrations 
consistently decreased from baseline values for patients who 
received natalizumab, while CRP concentrations remained Biologics: Targets & Therapy 2008:2(2) 281
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essentially unchanged or slightly increased for those who 
received placebo. At week 12, 23% of natalizumab-treated 
patients had CRP concentrations below the upper limit of 
normal compared with 8% of patients receiving placebo 
(p  0.001). Adverse events occurred at similar frequen-
cies in the placebo and natalizumab groups, and no deaths 
occurred during this short-term induction study. Nine percent 
of patients in the natalizumab group and 13% of patients in 
the placebo group discontinued treatment due to an adverse 
events (p = NS). Serious adverse events occurred in 5% of 
patients in the natalizumab group compared with 10% in the 
placebo group (such as exacerbation of CD, one basal cell 
carcinoma, B-cell lymphoma in patient receiving a combi-
nation therapy with 6-mercaptopurine). Infections occurred 
in a greater proportion of patients in the natalizumab group 
than placebo group (35% vs 30%, respectively). This was 
primarily due to the more frequent occurrence of nasophar-
yngitis in the natalizumab group compared with placebo 
group. No opportunistic infections, including progressive 
multifocal leukoencephalopathy (PML), occurred during the 
study. Acute infusion reactions occurred in 9% of patients 
treated with natalizumab compared with 7% of the placebo
group. Acute hypersensitivity-like reactions were determined 
before unblinding by a medical review of all adverse reac-
tions that led to the interruption or discontinuation of study 
drug (adverse reactions that occurred within 24 hours of an 
infusion). This reaction occurred in 4% patients treated with 
natalizumab and 1% in the placebo group. The positivity 
to anti-natalizumab antibodies was found in 9.5% patients. 
Concomitant immunosuppressive and corticosteroid therapy 
slightly decreased the rate of formation of anti-natalizumab 
antibodies. The presence of anti-natalizumab antibodies 
did not appear to have any impact on the overall incidence 
of adverse events, but seem to cause more acute infusion 
reactions and hypersensitivity-like reactions. The presence 
of antibodies did not appear to signiﬁ  cantly affect response 
rates in this short-term study.
Adverse events
Natalizumab was generally well tolerated and the safety 
proﬁ  le observed in the four included studies was similar. 
Adverse events occurred infrequently and were experienced 
by a similar proportion of natalizumab and placebo-treated 
patients. Presenting in more than 10% during the clinical 
trials were: headache, worsening of CD, abdominal 
pain, artharlgia, colitis, influenza syndrome, infection, 
nausea, vomiting, fatigue, pharyngitis, infusion reactions, 
hypersensitivity-like reactions, and the development of 
antibodies against natalizumab (MacDonald and McDonald 
2007). This suggests that the antibody did not interfere with 
neutrophil functions that are independent of α4 integrins 
and are necessary to combat bacterial and fungal infections. 
Concomitant use of immunosuppressive agents and 
corticosteroids may be protective against anti-natalizumab 
antibody formation, but in the ENACT trials the low overall 
rates of immunogenicity precluded statistical comparisons 
(Sandborn et al 2005). When persistent anti-natalizumab 
antibodies were present, they appeared to be associated 
with infusion reactions, hypersensitivity reactions, and 
loss of efﬁ  cacy. All of the included trials lacked adequate 
power to detect rare or serious adverse events (Sandborn 
et al 2005). Chronic inhibition of integrins action could 
also have undesirable effects that are independent of the 
immunogenicity of the pharmacological inhibitor. In fact, 
integrins are required also for normal morphogenesis of the 
inner cell mass and are essential mediators of growth and 
survival of cells of the inner cell mass (Stephens et al 1995). 
This could suggest avoiding the use of agents that inhibit 
these pathways during pregnancy.
Some opportunistic infections seem to be selectively 
associated with individual treatments, presumably illuminat-
ing mechanisms important in speciﬁ  c immune defence; for 
example, the reactivation of latent tuberculosis after anti-TNF 
therapy, illuminating the key role played by TNFα in the 
control of mycobacyteria and other intracellular pathogens 
(Podolsky 2005).
Recently, 2 patients with multiple sclerosis treated with 
natalizumab in combination with interferon β-1a and 1 
patient with CD treated with natalizumab in combination 
with azathioprine developed progressive PML resulting in 
2 patient deaths (Kleinschmidt-DeMasters and Tyler 2005; 
Langer-Gould et al 2005; Van Assche et al 2005). The CD 
patient received 3 doses of natalizumab in combination with 
azathioprine during ENACT-1, 9 doses of placebo in com-
bination with azathioprine during ENACT-2, and 5 doses of 
natalizumab without concurrent azathioprine during an open 
label extension study (Sandborn et al 2005).
PML is a serious opportunistic infection of the central 
nervous system for which there is no speciﬁ  c treatment. PML 
is caused by the reactivation of quiescent JC polyomavirus. 
JC virus is a ubiquitous infection acquired during childhood 
that remains dormant in bone marrow, kidney epithelia, 
spleen, and gastrointestinal tract. Antibodies against JC virus 
are detectable in at least 80% of adults (Berger and Koralnik 
2005). However, humoral immunity is insufﬁ  cient to pre-
vent the spread of the virus to the central nervous system. Biologics: Targets & Therapy 2008:2(2) 282
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Activation of the latent virus and subsequent dissemination 
have been causally linked to the development of PML. 
Intermittent reactivation, with shedding of live virus in the 
urine, has been well documented in cross-sectional studies 
in healthy adults and pregnant women, but the phenomenon 
is poorly understood. Spread of the virus to the central 
nervous system and the subsequent development of PML 
occur in immunocompromised people, most commonly those 
infected with HIV, but also in some patients with lymphoma, 
sarcoidosis, and medication-induced immunosuppression 
(Berger and Koralnik 2005). In response to the problem the 
manufactures of natalizumab in consultation with regulatory 
authorities and the National Institutes of Health conducted 
a retrospective investigation to assess the risk of PML in 
natalizumab-treated patients (Yousry et al 2006). All adverse 
events were reviewed to identify any unrecognized occur-
rences of PML, and exposed patients underwent neurological 
examination and magnetic resonance scanning. A total of 
3826 patients who had participated in recent clinical trials 
of natalizumab (multiple sclerosis, CD, and rheumatoid 
arthritis) were recruited for the evaluation. The incidence of 
PML associated with exposure to natalizumab is 1.0 cases per 
1000 patients (95% CI 0.2–2.8 per 1000) in this population 
who received a mean of 17.9 monthly doses of natalizumab. 
The investigation found no new conﬁ  rmed cases of PML. 
The duration of exposure required to put patients at risk for 
PML is not known. Patients who were diagnosed with PML 
received 8–37 monthly infusions. The median exposure in 
the evaluated patients was 30 infusions among multiple 
sclerosis patients and 7 among CD or rheumatoid arthritis 
patients (Yousry et al 2006). Some authors (Adelman et al 
2005; Berger and Koralnik 2005) suggest that the prospective 
measurement of the JC viral load in plasma and the reduction 
or discontinuation of natalizumab treatment, if JC virus is 
detected in the blood, might prevent the development of PML 
in this setting. A similar method has been used successfully 
to prevent nephropathy caused by the JC virus-related BK 
polyomavirus in kidney-transplant patients (Brennan et al 
2005). Further analysis of serum samples obtained from the 
investigation will help to determine the feasibility of preventive 
strategies against the development of PML in patients treated 
with natalizumab or related drugs in the future. Finally, it 
should be noted that JC virus has also been potentially linked 
to gastrointestinal tract cancers, particularly those of the 
colon (Casini et al 2005; Niv et al 2005); reactivation of the 
virus may contribute to the chromosomal-instability pathway. 
If correct, this would raise at least a hypothetical concern 
about the use of this agent in patients with IBD.
Critical comments and conclusions
Pooled data from the four studies (MacDonald and McDonald 
2007) suggest that natalizumab is effective for induction 
of clinical response and remission in some patients with 
moderately to severely active CD (remission [NNT = 17] at 
2 weeks and response at 4 weeks with 1 infusion 300 mg or 
3–4 mg/kg; remission [NNT = 10] at 6 weeks with 2 infusions 
3 or 4 mg/kg; remission [NNT = 12] and clinical response 
[NNT = 10] at 12 weeks with 3 infusions) (these comparisons 
were not statistically signiﬁ  cant at 10 weeks follow-up).
Natalizumab is particularly beneﬁ  cial for patients with 
active inﬂ  ammation or chronically active disease despite the 
use of conventional therapies (MacDonald and McDonald 
2007). Indeed, subgroup analyses demonstrated signiﬁ  cantly 
greater clinical response and remission rates for natalizumab 
compared with placebo in patients with elevated CRP levels, 
and active disease despite the use of immunosuppressant or 
prior anti-TNFα therapy (MacDonald and McDonald 2007). 
These beneﬁ  ts were apparent for both short-term and long-
term treatment (clinical remission [NNT = 8] and response 
[NTT = 7] at 10 and 12 weeks with 3 infusions of natalizumab 
4 mg/kg without previous different therapies; NNT = 6 in 
patients using immunosuppressants and NNT = 5 in patients 
previously treated with anti-TNFα therapy). The ENCORE 
study supports the efﬁ  cacy of natalizumab as induction 
therapy for CD patients with active inﬂ  ammation. Indeed, 
3 infusions of natalizumab (300 mg) were also signiﬁ  cantly 
superior to placebo for induction of clinical remission and 
response at 8 and 12 weeks (Targan et al 2007) in patients 
with high CRP. Although natalizumab is ﬁ  nding a new role in 
the management of CD, many problems about its utilization 
in CD remain unsolved and need to be discussed.
Placebo response
The use of placebo in randomized controlled trials is the gold 
standard for evaluating the effectiveness of new therapies. 
However, the placebo response rate is variable and may be 
affected by multiple factors. There were pronounced placebo 
remission and response rates in the natalizumab studies. In 
the Ghosh et al 2003 trial the remission and response rates 
increased in the placebo group from week 2 to week 12 
(from 10% to 27% for remission rate and from 30% to 43% 
for response rate). In the ENACT-1 trial there was a high 
placebo response rate (49%) compared to natalizumab (56%) 
at 10 weeks, making it difﬁ  cult to observe a treatment effect 
(Sandborn et al 2005). The high frequency and durability of 
the placebo response in the ENACT-2 study arouse concern 
that the results may have been partially confounded by the Biologics: Targets & Therapy 2008:2(2) 283
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enrolment of some patients with little or no active disease. 
In the most recent trial (Targan et al 2007) the response rate 
at week 8 occurred in 32% of placebo group and this value 
was increasing at 12 weeks with 44% with clinical response 
and 25% with remission in the placebo group. Knowledge 
of the placebo outcomes and understanding speciﬁ  c study 
features that inﬂ  uence these outcomes is important for design-
ing future clinical trials evaluating therapy.
Dosage and timing schedule
The optimal dosage and timing schedule for induction of 
remission and response using natalizumab therapy remains 
to be completely determined. Ghosh et al (2003) looked 
at the efﬁ  cacy of 2 different dosages of natalizumab in 
comparison to placebo and did not ﬁ  nd any advantage for 
2 infusions of 6 mg/kg natalizumab over 3 mg/kg. Three of 
the included studies dosed patients every 4 weeks for a total 
of 2 infusions and 3 infusions. No studies to date have tried 
a different timing schedule.
Disease behavior and location
The ENACT-1/2 and ENCORE trials (Sandborn et al 2005) 
did not enrol patients with ﬁ  stulazing CD. Although Gordon 
et al (2001) and Ghosh et al (2003) included patients with 
ﬁ  stulizing CD (30% and 15.3%, respectively), they did not 
make any comments on the efﬁ  cacy of natalizumab for ﬁ  s-
tula healing and closure. Moreover, there are no published 
data that consider the natalizumab efﬁ  cacy on the basis 
of different patients behavior and location and their evolution 
during the disease history.
Deﬁ  nition of outcome
In all published studies mucosal healing was not evaluated as an 
outcome. Clinical remission and response were based on CDAI 
values and laboratories analyses. Considering the heterogeneity 
of CD, the assessment of remission is more complex. Since the 
CDAI relies heavily on symptomatic parameters, it does not 
come as a surprise that its correlation with endoscopic scores or 
histological activity is weak (Modigliani et al 1990; Oldenburg 
and Hommes 2007). Presently, an unambiguous clinical and 
endoscopic deﬁ  nition of remission in CD is lacking, hampering 
the efforts of clinicians to formulate clear therapeutic objective 
for the long term, especially in the evaluation of new biological 
therapies efﬁ  cacy in clinical trials.
Previous therapy
In all published studies the median time of wash-out of 
immunosuppressive therapy was within 2 or 4 months from 
the starting time of stable dosage (from 38% to 17% in the 
placebo group and from 38% to 18% in the natalizumab-
treated group of patients with immunosuppression therapy). 
In the ENCORE study there was no speciﬁ  cation about the 
time needed to consider a stable dosage of previously started 
immunosuppressive therapy. Considering the inclusion 
criteria there was a short time to wash-out with the previous 
treatment (steroids and immunosuppressive drugs) which can 
inﬂ  uence the results about the efﬁ  cacy of natalizumab. It is 
important to highlight that the effect of the immunosuppres-
sive drugs starts after 2–6 months of treatment. This could 
be too short a time to be sure about the independent effect 
of natalizumab.
Adverse events
Natalizumab was approved by the FDA for the treatment of 
relapsing-remitting multiple sclerosis in December 2004. Its 
use in clinical practice and clinical trials was suspended in 
February 2005 because of the development of PML in patients 
treated with natalizumab (MacDonald and McDonald 2007). 
The FDA approved natalizumab for CD in January 2008, and 
approved a supplemental biologics licence application for 
the reintroduction of natalizumab monotherapy treatment for 
relapsing-remitting multiple sclerosis in June 2006. Natali-
zumab was also approved for this indication by the European 
Medicines Evaluation Agency (EMEA) in June 2006 and 
Health Canada in October 2006 (MacDonald and McDonald 
2007). Actually we cannot neglect the previous reported 
observation of PML cases after natalizumab treatment. These 
observations provide a unique and unexpected window into 
our understanding of the pathogenesis of PML and force us 
to reconsider the potential risks associated with  the inhibi-
tion of lymphocyte trafﬁ  cking. Our understanding of the ratio 
between beneﬁ  ts and risks of natalizumab in patients with CD 
is not sufﬁ  cient to offer a deﬁ  nitive answer. Efforts should be 
focused not only on deﬁ  ning the true therapeutic efﬁ  cacy of 
this but also on gaining a more precise understanding of the 
mechanisms of action and risk of treatment with antibody 
against α4 integrins. For these reasons, natalizumab should 
be targeted as a second-line biological therapy to patients 
who have frequent and debilitating recurrences of CD with 
close surveillance by magnetic resonance scanning and serum 
analysis for the earliest signs of JC virus (Podolsky 2005). 
In conclusion, it is important in the future to stay mindful of 
deﬁ  ning the true therapeutic efﬁ  cacy and on gaining more 
precise understanding of the mechanisms of action and risks 
of treatment with antibody against α4-integrin and with other 
new biological agents developed.Biologics: Targets & Therapy 2008:2(2) 284
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Evaluation Agency; ENCORE, Efﬁ  cacy of Natalizumab 
in Crohn’s disease Response and Remission; FDA, Food 
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